Ben R. Taylor is CFO at RECURSION PHARMACEUTICALS, INC. (RXRX). They have made 1 open-market trade across 1 company since 2019, most recently 2026-09-15.
CIK 0001712276
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2019, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RXRX | SELL · 10b5-1 | 2026-03-17 | 2026-03-18 | $3.39 | $27K | -12.1% | +17.0% | -1.2% |
| RXRX | SELL · 10b5-1 | 2026-02-18 | 2026-02-19 | $3.08 | $41K | -2.7% | -11.3% | -18.8% |
| RXRX | SELL · 10b5-1 | 2025-12-29 | 2025-12-30 | $4.18 | $179K | +17.3% | +5.4% | -30.7% |
| TYME | BUY | 2019-06-14 | 2019-06-17 | $1.01 | $10K | +0.9% | +13.6% | +45.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.